AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01621542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT2725
Description: WT2725 injection Study drug will be administered every 1-4 weeks
Study NCT04057534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard therapy for AUD plus Chess-based cognitive treatment
Description: Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition.
Study NCT04057534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy for AUD
Description: Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine.
Study NCT04057534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment
Description: Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smoking cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition.
Study NCT04057534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy for TUD
Description: Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smokind cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week.
Study NCT03752775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Robot assisted upper limb rehabilitation
Description: The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
Study NCT03752775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted upper limb rehabilitation
Description: The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
Study NCT03752775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted upper limb rehabilitation
Description: The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
Study NCT04352192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of biceps brachii muscle.
Study NCT02445625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI to train joint attention in ASD
Description: The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
Study NCT04326699 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral SIJ injection
Description: under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
Study NCT03259750 — intervention group
Intervention type: OTHER
Intervention: Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire
Description: Self reported outcome instrument
Study NCT04838665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% cyclopentolate and 2.5% phenylephrine
Description: Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
Study NCT04838665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% cyclopentolate and 2.5% phenylephrine
Description: Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
Study NCT04838665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide + 0.5% phenylephrine
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine
Study NCT04838665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% tropicamide + 0.5% phenylephrine
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine
Study NCT04838665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide + 0.5% phenylephrine with a cotton wick
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
Study NCT04838665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% tropicamide + 0.5% phenylephrine with a cotton wick
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
Study NCT03476564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
Study NCT03476564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit E
Description: will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
Study NCT01995578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose 5'-azacitidine
Description: 5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
Study NCT02803528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is going to be used as the direct pulp capping material
Study NCT02803528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: MTA is going to be used as the direct pulp capping material in the second group
Study NCT02633410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral tunnel creation
Description: Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
Study NCT02452281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: 3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
Study NCT02452281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
Study NCT01378104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa 2a (pegasys)
Description: dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
Study NCT01378104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a (pegasys)
Description: These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
Study NCT02912416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Study NCT02912416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00002860 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Complete surgical resection of metastatic melanoma
Study NCT01859468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amorphous calcium carbonate
Study NCT01859468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00096668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOCOSOL(R) Paclitaxel
Study NCT03644654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care group
Description: Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. Fluid boluses will be used according to anesthesiologists decision (timing and amount of fluids). In case of drop of mean arterial pressure (MAP) below 65 mmHg norepinephrine will be started (with initial bolus of 5 - 10 ug).
Study NCT03644654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive monitoring group
Description: Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. In case of hypotension (defined as a mean arterial pressure below 65 mmHg), the intervention will be led according to a protocol based on cardiac index, systemic vascular resitance and stroke volume variation (SVV) values (ClearSight, Edwards).
Study NCT05221801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: angle of inclination
Description: The measurement would be done in seat inclination angles of 5,15,30,45 degrees.
Study NCT05221801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food type
Description: the swallowing was tested with 3 food types
Study NCT04215614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and Bupivacaine solution
Description: 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
Study NCT04215614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Costoclavicular block
Description: Ultrasound-guided costoclavicular brachial plexus block
Study NCT04215614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Sagittal block
Description: Ultrasound-guided lateral sagittal brachial plexus block
Study NCT05584254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yeast-beta glucan
Study NCT04714736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography using DyeVert system
Description: Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using DyeVert system.
Study NCT04714736 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Coronary angiography using conventional manual injection syringe.
Description: Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using conventional manual injection syringe.
Study NCT01195753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HHLivC
Description: multiple infusion of liver cells
Study NCT03128476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essence of Chicken
Description: Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.
Study NCT03128476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Energy matched)
Study NCT02154542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurovent Monitor XIII
Study NCT02748850 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: a blood sample 20 milliliter
Study NCT02748850 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Stem cell donation
Description: The volume of stem cells remained in the tube is recovered
Study NCT00455013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
Study NCT00455013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thymoglobulin
Description: Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
Study NCT00455013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
Study NCT00455013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
Study NCT00455013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
Study NCT00455013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
Study NCT00455013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil (MMF)
Description: Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
Study NCT02896829 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interruption of the treatment by Imatinib
Study NCT01776736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posture Correction Girdle
Description: Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
Study NCT01765842 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Only one cycle of rituximab will be administered in this arm.
Study NCT01765842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Only one cycle of rituximab will be administered in this arm.
Study NCT03364361 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture
Description: Participants will receive a six-point standardized stress acupuncture (SSA) treatment once a week for 4 weeks. The SSA consists of GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. This acupuncture protocol has been used as an effective treatment for stress-related symptoms in the operational theater.
Study NCT04062526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
Study NCT04728022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program
Description: Mentored high school summer research program
Study NCT03858036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ricrolin+
Description: 1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
Study NCT03858036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VEGA UV-A system
Description: The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
Study NCT02163083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG
Description: Improvement of detection of positive lymphnodes
Study NCT01020591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic evaluation
Description: evaluation of movement and tissue mobility
Study NCT01020591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic evaluation with treatment
Description: osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
Study NCT04719494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic balance walking training
Description: Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
Study NCT02611804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Study NCT02611804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Study NCT02611804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02713165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisins
Description: Participants will consume 84g of raisins per day for 14 days.
Study NCT01091584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: distress thermometer
Description: to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
Study NCT00514774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodiol
Description: ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28
Study NCT00514774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 600mg twice daily for study days 0 through 28
Study NCT00759733 — intervention group
Intervention type: PROCEDURE
Intervention: echocardiography
Description: A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.